{"id":"ala-cpn10","_chembl":{"chemblId":"CHEMBL263781","moleculeType":"Protein","molecularWeight":"1410.61"},"_dailymed":null,"_scrapedAt":"2026-03-28T05:52:00.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123070,"model":"claude-sonnet-4-5-20250929"},"description":"Ala-Cpn10 is an investigational therapeutic agent developed by Invion, Inc., currently in Phase 1 clinical development. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this early stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT01838694","phase":"PHASE1, PHASE2","title":"Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.","status":"COMPLETED","sponsor":"Invion, Inc.","startDate":"2013-07","conditions":"Lupus Erythematosus, Systemic","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Ala-Cpn10","genericName":"Ala-Cpn10","companyName":"Invion, Inc.","companyId":"invion-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ala-Cpn10 is a protein-based intervention being studied in a clinical trial for the treatment of Systemic Lupus Erythematosus (SLE). The trial, NCT01838694, is investigating the safety, tolerability, pharmacokinetics, and biochemical activity of intravenous Ala-Cpn10 administration in subjects with mild to moderate SLE.","enrichmentLevel":2,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}